HK1255481A1 - 用於治療hcv的方法 - Google Patents

用於治療hcv的方法

Info

Publication number
HK1255481A1
HK1255481A1 HK18114657.5A HK18114657A HK1255481A1 HK 1255481 A1 HK1255481 A1 HK 1255481A1 HK 18114657 A HK18114657 A HK 18114657A HK 1255481 A1 HK1255481 A1 HK 1255481A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating hcv
hcv
treating
Prior art date
Application number
HK18114657.5A
Other languages
English (en)
Inventor
Barry M Bernstein
Sandeep Dutta
Wei Liu
Thomas J Podsadecki
Andrew Campbell
Rajeev M Menon
Chih-Wei Lin
Tianli Wang
Walid M Awni
Sven Mensing
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1255481A1 publication Critical patent/HK1255481A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18114657.5A 2015-07-08 2018-11-15 用於治療hcv的方法 HK1255481A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190045P 2015-07-08 2015-07-08
US201562266954P 2015-12-14 2015-12-14
PCT/US2016/041334 WO2017007934A1 (en) 2015-07-08 2016-07-07 Methods for treating hcv

Publications (1)

Publication Number Publication Date
HK1255481A1 true HK1255481A1 (zh) 2019-08-16

Family

ID=56497883

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114657.5A HK1255481A1 (zh) 2015-07-08 2018-11-15 用於治療hcv的方法

Country Status (10)

Country Link
US (1) US20180177779A1 (zh)
EP (1) EP3319604A1 (zh)
JP (2) JP6808660B2 (zh)
CN (1) CN107921038A (zh)
AU (1) AU2016291154B2 (zh)
BR (1) BR112018000383A2 (zh)
CA (1) CA2991417A1 (zh)
HK (1) HK1255481A1 (zh)
MX (1) MX2018000240A (zh)
WO (1) WO2017007934A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN110302361A (zh) 2014-04-02 2019-10-08 艾伯维公司 治疗hcv的方法
US20170248953A1 (en) * 2016-02-25 2017-08-31 Ford Global Technologies, Llc Autonomous peril control
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
WO2020106835A1 (en) 2018-11-20 2020-05-28 Abbvie Inc. Methods for treating acute hcv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
DK2618831T3 (en) 2010-09-21 2016-04-04 Enanta Pharm Inc Macrocyclic prolinafledte HCV serine protease inhibitors
DE112012003457T5 (de) 2011-10-21 2015-03-12 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
RU2665365C2 (ru) * 2012-09-18 2018-08-29 Эббви Инк. Способы лечения гепатита с
BR112015006056A2 (pt) * 2012-09-18 2017-07-04 Abbvie Inc métodos para tratar hcv
LT2968301T (lt) * 2013-03-14 2017-05-25 Abbvie Inc. Dviejų antivirusinių vaistų derinys, skirtas hepatito c gydymui
EP3060216A4 (en) * 2013-10-25 2017-06-21 Abbvie Inc. Methods for treating hcv
CN110302361A (zh) * 2014-04-02 2019-10-08 艾伯维公司 治疗hcv的方法

Also Published As

Publication number Publication date
WO2017007934A1 (en) 2017-01-12
JP2018519321A (ja) 2018-07-19
JP2021050223A (ja) 2021-04-01
JP6808660B2 (ja) 2021-01-06
EP3319604A1 (en) 2018-05-16
MX2018000240A (es) 2018-03-14
AU2016291154B2 (en) 2021-10-21
AU2016291154A1 (en) 2018-01-25
CN107921038A (zh) 2018-04-17
CA2991417A1 (en) 2017-01-12
BR112018000383A2 (pt) 2018-09-18
US20180177779A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
HUE057928T2 (hu) Coronaviridae családba tartozó vírus okozta fertõzések kezelésére szolgáló eljárások
GB201500989D0 (en) Process
HK1244217A1 (zh) 用於治療蛋白質病的方法
GB201502893D0 (en) Process
GB201502894D0 (en) Process
HK1255481A1 (zh) 用於治療hcv的方法
GB201506572D0 (en) Process
GB201501952D0 (en) Process
GB201505311D0 (en) Process
HK1248133A1 (zh) 治療神經母細胞瘤的方法
GB201507170D0 (en) Process
GB201503635D0 (en) Process
GB201501953D0 (en) Process
GB201500990D0 (en) Process
GB201504948D0 (en) Process
GB201502814D0 (en) Process
GB201501423D0 (en) Process
GB201503607D0 (en) Process
IL254336A0 (en) A new treatment method
ZA201607068B (en) Methods for treating hypersomnia
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
GB201505981D0 (en) Process
GB201505712D0 (en) Process
EP3313398A4 (en) METHODS OF TREATING HCV
IL249616A0 (en) Methods for treating inflammation